Adcentrx Therapeutics

About Adcentrx Therapeutics

Adcentrx Therapeutics is a clinical-stage biotechnology company focused on accelerating breakthroughs in developing protein conjugate therapeutics for cancer and other life-threatening diseases. The company aims to improve patient treatment options by combining the targeting precision of biologics with the disease-fighting power of small molecule payloads.

Products & Services

Protein Conjugate Therapeutics:Next-generation targeted therapies for cancer and other life-threatening diseases, combining biologics' precision with small molecule payloads.

ADRX-0405 STEAP1 ADC:A therapy for gastric cancer, granted Orphan Drug Designation by the U.S. FDA.

Specialties

Protein Conjugate Therapeutics Cancer Treatment Targeted Therapies Biologics Small Molecule Payloads

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A+ T: - FT: Series A+	A: 51000000 MR: - FA: 51 Million FAN: 51000000	D: 2023-12-05 FD: 2023-12-05	3 investors
2	RT: Series A+ T: - FT: Series A+	A: 38000000 MR: - FA: $38 million FAN: 38000000	D: 2023-04-24 FD: 2023-04-24	6 investors

Series A+ Latest

2023-12-05

$51.0M

3 investors (Pro only)

Series A+ 2023-04-24

$38.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mike Varney

Executive Vice President, Head of Genentech Research and Early Development

K

Kerry Blanchard

Co-founder, Chairman, and CEO of Perpetual Medicines

H

Hui Li

President and CEO

P

Pia Challita-Eid

Chief Scientific Officer

M

Meng Jiang

Chief Financial Officer

M

Maojun Guo

Senior Vice President, Research

View 7 more team members with Pro

Unlock Full Team Directory

Recent News